Process and Analytical Development of Drug-Fc Conjugates (DFCs)

Time: 11:30 am
day: Day Two


  • Evaluate Cidara Therapeutics’ DFCs developments to address serious diseases
  • Compare and expand upon the strengths of small molecules and antibody therapeutics using the uniquely tunable DFCs platform
  • Address the unique challenges associated with each DFCs product development, considering disease area, dose regimen, and properties